References
- Kalra S, Kalra B, Agrawal N. Combination therapy in hypertension: an update. Diabetol Metabol Synd 2010;2:44,1–11
- Lerebours G, Antony I. Clinical review of perindopril erbumine in thetreatment of hypertension. Can J Cardiol 1994;Suppl D:3D–7D
- Alfakih K, Hall AS. Effects of perindopril treatment on hemostaticfunction in patients with essential hypertension. Nutr Metab Cardiovasc 2004;14:259–269
- Ceconi C, Fox KM, Remme WJ, et al. ACE inhibition with perindopril and biomarkers of atherosclerosis and thrombosis: results from the PERTINENT study. Atherosclerosis 2009;204:273–275
- Remko M. Acidity, lipophilicity, solubility, absorption and polar surface area of some ACE ınhibitors. Chem Pap 2007;61:133–141
- Jain DS, Subbaiah G, Sanyal M, et al. First LC-MS/MS electrospray ionization validated method for the quantification of perindopril and its metabolite perindoprilat in human plasma and its application to Bioequivalence study. J Chrom B 2006;837:92–100
- Ceconi C, Francolini G, Bastianon D, et al. Differences in the effect of angiotensin-converting enzyme inhibitors on the rate of endothelial cell apoptosis: in vitro and in vivo studies. Cardiovasc Drugs Ther 2007;21:423–429
- Verpooten GA, Genıssel PM, Thomas JR, Broe EDe. Single dose pharmacokinetics of perindopril and its metabolites in hypertensive patients with various degrees of renal insufficiency. Br J Clin Pharmacol 1991;32:187–192
- Setiawati E, Deniati SH, Yunaldi DA, et al. Bioequivalence study of two perindopril erbumine tablet formulations in healthy volunteers. Arnzneimittelforschung 2011;61:234–238
- Sica DA. Dosage considerations with perindopril for systemic hypertension. Am J Cardiol 2001;88(Suppl):13i–18i
- Parker E, Aarons L, Rowland M, Resplandy G. The pharmacokinetics of perindoprilat in normal volunteers and patients: influence of age and disease state. Eur J Pharm Sci 2005;26:104–113
- Thiollet M, Funck-Brentano C, Grange JD, et al. The pharmacokinetics of perindopril in patients with liver cirrhosis. Br J Clin Pharmacol 1992;33:326–328
- Lees KR, Green ST, Reid JL. Influence of age on the pharmacokinetics and pharmacodynamics of perindopril. Clin Pharmacol Ther 1988;44:418–425
- Wagner L, Fekete A, Rudolf A, et al. The safe introduction of angiotensin-converting enzyme inhibitor in renal allograft recipients. Transplant Proc 2012;44:2151–2153
- Keith NG, Cara M, Hildreth AP, et al. Angiotensin-converting enzyme inhibitor limits pulse-wave velocity and aortic calcification in a rat model of cystic renal disease. Am J Physiol Renal Physiol 2011;301:F959–F966
- Al Ali SSH, Al-Qubaisi M, Hussein MZ, et al. Controlled release and angiotensin-converting enzyme inhibition properties of an antihypertensive drug based on a perindopril erbumine-layered double hydroxide nanocomposite. Int J Nanomed 2012;7:2129–2141
- Bjanha SB, Ellaiah P, Roy HK, et al. Formulation and evaluation of perindopril sublingual tablets. Int J Res Pharm Biomed Sci 2011;2:1193–1198
- Ratnaparkhi Mukesh P, Jagadale Sachin K, Patil Pradeep S, Dhiwar Suresh B. Formulation development and evaluation of taste masked orally disintegrating tablets of perindopril erbumine by direct compression method. Int J Drug Dev Res 2012;4:374–394
- Satyabrata B, Ellaiah P, Chandan M, et al. Design and in vitro evaluation of mucoadhesive buccal tablets of perindopril prepared by sintering technique. Int J Pharm Technol Res 2010;2:1810–1823
- Swarbrick J. Encyclopedia of pharmaceutical technology, 3rd ed., Vol. 1. New York: Informa Healthcare USA, Inc.; 2007:3674
- FDA – Guidance for Industry, Q1A(R2) Stability Testing of New Drug Substances and Products
- FDA – Guidance for Industry, DissolutionTesting of Immediate Release Solid Oral Dosage Forms
- Patil Pradeep S, More Akshata K, Kadam S, et al. Formulation and evaluation of orodispersible tablets of perindopril erbumine using natural superdisintegrant. JDDT 2013;3:44–48